Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.0%, Dividend Yield is 4.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%
Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -61%
Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 30x
1 Low stock price volatility
Vol 12M is 40%
  Key risks
MDLN key risks include [1] a substantial debt load from its leveraged buyout, Show more.
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Diabetes Management, Show more.
  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.0%, Dividend Yield is 4.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%
1 Low stock price volatility
Vol 12M is 40%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Diabetes Management, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -61%
4 Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 30x
5 Key risks
MDLN key risks include [1] a substantial debt load from its leveraged buyout, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Medline (MDLN) stock has remained largely at the same level since it went public on 12/17/2025 because of the following key factors:

1. Initial Post-IPO Price Stabilization After Strong Debut.

Medline's stock experienced a significant surge on its IPO day, closing at $41.00 on December 17, 2025, a 41.38% increase from its $29.00 offering price. Following this enthusiastic market debut, it is common for a newly public company's stock to stabilize around its initial post-IPO trading range as market sentiment normalizes and investors evaluate its long-term fundamentals. The stock's price near $41.07 as of March 12, 2026, reflects this period of stabilization after the initial excitement.

2. Mixed Q4 2025 Earnings Performance Coupled with Tariff Headwinds.

Medline's fourth-quarter 2025 earnings, reported on February 25, 2026, presented a mixed financial picture. While the company achieved strong net sales of $7.8 billion, an increase of 14.8% year-over-year, its net income decreased by 37.7% to $180 million. Adjusted EBITDA remained largely flat, primarily due to higher costs of goods sold and increased operating expenses, including a significant impact from tariffs. Medline also forecast a net tariff impact of approximately $490 million for 2026, indicating ongoing pressure on profit margins that likely tempered investor optimism despite solid sales growth.

Show more

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

11/30/2025 to 3/29/2026
ReturnCorrelation
MDLN  
Market (SPY)-5.3%16.1%
Sector (XLV)-8.7%10.2%

Fundamental Drivers

null
null

Market Drivers

8/31/2025 to 3/29/2026
ReturnCorrelation
MDLN  
Market (SPY)0.6%16.1%
Sector (XLV)5.2%10.2%

Fundamental Drivers

null
null

Market Drivers

2/28/2025 to 3/29/2026
ReturnCorrelation
MDLN  
Market (SPY)9.8%16.1%
Sector (XLV)-2.1%10.2%

Fundamental Drivers

null
null

Market Drivers

2/28/2023 to 3/29/2026
ReturnCorrelation
MDLN  
Market (SPY)69.4%16.1%
Sector (XLV)18.4%10.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MDLN Return----2%1%3%
Peers Return17%23%17%10%49%2%179%
S&P 500 Return27%-19%24%23%16%-5%72%

Monthly Win Rates [3]
MDLN Win Rate----100%67% 
Peers Win Rate53%60%60%55%72%60% 
S&P 500 Win Rate75%42%67%75%67%33% 

Max Drawdowns [4]
MDLN Max Drawdown-----4%-7% 
Peers Max Drawdown-6%-7%-11%-4%-0%-4% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-5% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: MCK, CAH, COR, JNJ, MDT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)

How Low Can It Go

MDLN has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,100 days1,480 days

Compare to MCK, CAH, COR, JNJ, MDT

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Medline (MDLN)

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

AI Analysis | Feedback

1. Amazon for medical supplies.
2. Grainger for the healthcare industry.

AI Analysis | Feedback

  • Medical-Surgical Products: A vast portfolio of consumable medical products, including surgical and procedural kits, gloves, protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products.
  • Supply Chain Solutions: Comprehensive services that optimize and manage the distribution and logistics of medical-surgical products for healthcare providers.
  • Prime Vendor Services: Long-term agreements where Medline acts as the consolidated distributor and logistics provider for customers' complete medical-surgical product needs.

AI Analysis | Feedback

Medline (MDLN) primarily sells its medical-surgical products and supply chain solutions to other companies and organizations within the healthcare sector.

The provided background information does not name specific major customer companies. Instead, it describes the broad categories of healthcare facilities and points of care that Medline serves:

  • Hospitals
  • Surgery centers
  • Physician offices
  • Post-acute facilities

AI Analysis | Feedback

null

AI Analysis | Feedback

Jim Boyle, Chief Executive Officer

Jim Boyle has served as Chief Executive Officer of Medline since 2023, having also joined its board of directors in the same year. He began his career at Medline in 1996 as a sales representative in San Antonio, Texas. Prior to his current role, he held positions as a Sales Trainer, Senior Account Manager, Division Vice President, and Senior Vice President. From 2018 to 2023, Mr. Boyle was an Executive Vice President, responsible for the strategic direction and execution of commercial functions across all healthcare sales divisions, as well as operations and logistics.

Mike Drazin, Chief Financial Officer

Mike Drazin joined Medline as Chief Financial Officer in 2018. Before Medline, he was Vice President, Global FP&A and Investor Relations at Illinois Tool Works Inc. from 2016 to 2018, and also served as Vice President, Global Financial Planning & Analysis from 2014 to 2018. From 2008 to 2014, he was a Group Controller at Illinois Tool Works Inc. Earlier in his career, Mr. Drazin held several financial leadership roles, including Group Controller at Click Commerce, Inc., Chief Financial Officer at Presutti Laboratories, Controller at CloudShield Technologies, Inc., Chief Financial Officer at Silicon Valley Internet Capital, and Senior Auditor at Arthur Anderson LLP.

Steve Miller, Chief Operating Officer

Steve Miller has served as Medline's Chief Operating Officer since January 1, 2025. He joined Medline in 2022 as Executive Vice President, Supply Chain, a role he held through 2024. Before joining Medline, Mr. Miller was Senior Vice President, Fulfillment Operations (2020-2022) and Vice President, People (U.S. Supply Chain) (2018-2020) at Walmart. He also held various supply chain, manufacturing operations, corporate strategy, and human resources positions at The Goodyear Tire & Rubber Company and Kimberly-Clark.

Amanda Laabs, Chief Product Officer

Amanda Laabs was appointed Chief Product Officer effective January 1, 2025. She joined Medline in 2006, initially in the medical textiles division. Ms. Laabs has advanced through a series of product management leadership roles, most recently serving as Executive Vice President, Medline Brand from 2023 until January 2025. Her previous roles include leading Medline's surgical drapes and gowns division and personal protection division, and managing the Dynacor kitting division, which involved integrating the acquired Centurion Medical Products company.

Billy Abrams, Executive Vice President, Supply Chain Solutions

Billy Abrams has been the Executive Vice President, Supply Chain Solutions since 2023. He joined Medline in 2009, holding positions such as Vice President of Preferred Healthcare, Executive Vice President of Real Estate & Assets, and President of the Distributed Products Division. While at Medline, he also served as President of Suture Express from 2019 to 2021. Prior to Medline, Mr. Abrams was Founding Principal at Hazel Ravine Partners, LLC from 2004 to 2008, and Chief Executive Officer at InfoPlus Corporation from 2001 to 2003.

AI Analysis | Feedback

  1. Supply Chain Disruptions and Reliance on Third-Party Suppliers: Medline sources products from over 500 global partners for its Medline Brand segment and offers approximately 145,000 third-party products through its Supply Chain Solutions segment. Any significant disruption to this extensive global supply chain due to geopolitical events, natural disasters, trade restrictions, or issues with key suppliers could severely impact Medline's ability to procure and deliver products, affecting sales and customer relationships.

  2. Intense Competition and Pricing Pressures: Despite being the largest provider of medical-surgical products and supply chain solutions, Medline operates in a competitive market. The company's strategy relies on driving cost savings for Prime Vendor customers and offering Medline Brand products at a cost-effective price. Competitors could offer more aggressive pricing or innovative solutions, potentially eroding Medline's market share, profitability, or the effectiveness of its Prime Vendor model and the associated "flywheel effect" that supports Medline Brand adoption.

  3. Dependence on the "Prime Vendor" Model and Ability to Maintain Customer Relationships: The "Prime Vendor" relationships are central to Medline's strategy, involving long-term agreements for consolidated distribution and logistics. A risk exists if Medline struggles to secure new Prime Vendor relationships, if existing Prime Vendor customers choose not to renew their agreements, or if they shift purchasing away from Medline Brand products, which offer higher margins. This could undermine a core part of their growth strategy and profitability drivers.

AI Analysis | Feedback

null

AI Analysis | Feedback

Medline (MDLN) operates in two main addressable markets: medical-surgical products and healthcare supply chain solutions.

For its medical-surgical products, Medline operates in an estimated global total addressable market of $375 billion. This market is further broken down into approximately $175 billion in the United States and about $200 billion outside the U.S..

For its supply chain solutions, the global healthcare supply chain management market size was valued at USD 3.93 billion in 2025 and is projected to grow to USD 11.35 billion by 2034. In North America, this market was valued at USD 1.91 billion in 2025, with the U.S. market specifically valued at USD 1.92 billion by 2026.

AI Analysis | Feedback

Medline (MDLN) is expected to drive future revenue growth over the next 2-3 years through a combination of strategic initiatives and sustained market demand. Key drivers include: * Expansion of Customer Base and Prime Vendor Relationships: Medline anticipates continued growth by securing new customer signings, particularly through its Prime Vendor model. The company reported $2.4 billion in new customer signings in 2025 and is targeting an additional $1 billion in new Prime Vendor signings for 2026. This strategy, coupled with a high retention rate for existing Prime Vendor customers, is expected to lead to the consolidation of med-surg spend with Medline. * Increased Penetration of Medline Brand Products: A significant driver involves increasing the adoption of Medline Brand products. This includes existing customers converting to Medline Brand offerings, which often provide superior value, and a concerted effort to boost brand penetration among both Prime Vendor and non-Prime Vendor customers. * New Product Development and Portfolio Expansion: Medline is investing in product innovation to sustain its growth trajectory. The company has expanded its Medline Brand product portfolio with approximately 190,000 products, including recent innovations such as the ComfortTemp patient warming system. * Channel Expansion and Strategic Investments: The company plans to grow by expanding into new care settings and channels, notably the non-acute space and facilities not affiliated with hospital systems. Strategic investments in automation and infrastructure are crucial to supporting this expansion and enhancing operational efficiency. * Selective Mergers and Acquisitions (M&A): Medline intends to pursue selective M&A opportunities to further extend its market reach and product lines. Recent examples, such as the contributions from the Coloplast Skincare and Microtek Surgical Solutions acquisitions, demonstrate the role M&A plays in its growth strategy.

AI Analysis | Feedback

Capital Expenditures

  • Medline maintains and invests in an expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and an owned fleet of over 2,000 MedTrans trucks to support its supply chain solutions and ensure next-day delivery to 95% of its U.S. customers.
  • The company operates 33 manufacturing facilities for its Medline Brand products, indicating ongoing capital allocation towards production capabilities.
  • Future capital expenditures are anticipated to support strategic objectives such as continuing channel expansion, developing new products, and scaling its international footprint.

Trade Ideas

Select ideas related to MDLN.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K02282026QDELQuidelOrthoInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%
CHE_2272026_Dip_Buyer_FCFYield02272026CHEChemedDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper02272026LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
0.0%0.0%0.0%
HAE_2202026_Dip_Buyer_FCFYield02202026HAEHaemoneticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
3.5%3.5%0.0%
IQV_2132026_Dip_Buyer_ValueBuy02132026IQVIQVIADip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
7.1%7.1%-3.0%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

MDLNMCKCAHCORJNJMDTMedian
NameMedline McKesson Cardinal.Cencora Johnson .Medtronic 
Mkt Price41.36860.16206.58312.45240.4587.14223.51
Mkt Cap33.6106.048.860.7578.9111.883.3
Rev LTM28,572397,958244,673325,77894,19335,483169,433
Op Inc LTM2,1335,8702,7584,14325,5966,6115,006
FCF LTM-9,6445,5023,60719,3135,4105,502
FCF 3Y Avg-4,7232,8062,20018,3835,2694,723
CFO LTM-10,4826,0994,28924,5307,2857,285
CFO 3Y Avg-5,4863,3472,75223,8627,0165,486

Growth & Margins

MDLNMCKCAHCORJNJMDTMedian
NameMedline McKesson Cardinal.Cencora Johnson .Medtronic 
Rev Chg LTM-15.5%10.1%7.4%6.0%6.9%7.4%
Rev Chg 3Y Avg-13.3%8.3%10.5%2.6%4.9%8.3%
Rev Chg Q21.9%11.4%18.8%5.5%9.1%8.7%10.2%
QoQ Delta Rev Chg LTM5.1%2.8%4.4%1.4%2.2%2.1%2.5%
Op Mgn LTM7.5%1.5%1.1%1.3%27.2%18.6%4.5%
Op Mgn 3Y Avg-1.4%1.0%1.1%25.6%18.5%1.4%
QoQ Delta Op Mgn LTM-0.9%0.1%0.0%0.0%1.5%-0.7%0.0%
CFO/Rev LTM-2.6%2.5%1.3%26.0%20.5%2.6%
CFO/Rev 3Y Avg-1.5%1.4%0.9%26.7%20.8%1.5%
FCF/Rev LTM-2.4%2.2%1.1%20.5%15.2%2.4%
FCF/Rev 3Y Avg-1.3%1.2%0.7%20.6%15.7%1.3%

Valuation

MDLNMCKCAHCORJNJMDTMedian
NameMedline McKesson Cardinal.Cencora Johnson .Medtronic 
Mkt Cap33.6106.048.860.7578.9111.883.3
P/S1.20.30.20.26.13.10.7
P/EBIT16.618.218.821.717.317.818.0
P/E29.824.429.337.321.624.226.9
P/CFO-10.18.014.123.615.314.1
Total Yield8.0%4.4%4.4%3.4%6.8%7.4%5.6%
Dividend Yield4.7%0.4%1.0%0.7%2.1%3.2%1.6%
FCF Yield 3Y Avg-5.5%7.8%4.3%4.6%4.7%4.7%
D/E0.40.10.20.10.10.30.2
Net D/E0.30.10.10.10.00.20.1

Returns

MDLNMCKCAHCORJNJMDTMedian
NameMedline McKesson Cardinal.Cencora Johnson .Medtronic 
1M Rtn-12.9%-12.8%-9.9%-16.0%-3.2%-10.0%-11.4%
3M Rtn-6.3%3.9%-0.8%-8.2%16.4%-9.0%-3.5%
6M Rtn0.9%13.3%35.2%2.1%35.4%-6.1%7.7%
12M Rtn0.9%29.3%53.3%14.3%51.0%2.6%21.8%
3Y Rtn0.9%143.5%189.3%101.3%71.4%21.3%86.3%
1M Excs Rtn-7.6%-3.8%-1.2%-7.0%6.6%-1.6%-2.7%
3M Excs Rtn1.5%12.3%7.9%0.2%24.5%-0.9%4.7%
6M Excs Rtn4.4%20.6%43.1%8.5%40.4%-1.9%14.5%
12M Excs Rtn-10.6%18.8%44.6%4.5%41.3%-8.8%11.6%
3Y Excs Rtn-60.9%93.1%149.9%47.3%12.3%-40.6%29.8%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA207964  READYPREP CHGchlorhexidine gluconatecloth11202018     

Financials

Segment Financials

Revenue by Segment
$ Mil202520242023
Supply Chain Solutions12,99211,61810,449
Medline Brand12,51511,61310,999
Total25,50723,23121,448


Short Interest

Short Interest: As Of Date3132026
Short Interest: Shares Quantity11.6 Mil
Short Interest: % Change Since 228202641.4%
Average Daily Volume9.8 Mil
Days-to-Cover Short Interest1.2 days
Basic Shares Quantity812.0 Mil
Short % of Basic Shares1.4%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/25/2026-3.6%-11.2%-14.6%
SUMMARY STATS   
# Positive000
# Negative111
Median Positive   
Median Negative-3.6%-11.2%-14.6%
Max Positive   
Max Negative-3.6%-11.2%-14.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202502/25/202610-K
09/30/202512/18/2025424B4
06/30/202510/28/2025S-1
12/31/202301/31/2025DRS/A

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hellman, & Friedman Capital Partners X (parallel), Lp Hellman & Friedman Capital Partners X (Parallel), L.P.Sell1222202528.375,079,306144,091,2762,521,676,655Form
2Hellman, & Friedman Capital Partners X (parallel), Lp HFCP X (Parallel - A), L.P.Sell1222202528.37547,30515,526,112262,937,064Form
3Hellman, & Friedman Capital Partners X (parallel), Lp Mend Partners II, L.P.Sell1222202528.37461,76013,099,346136,342,589Form
4Gic, Private Ltd Hux Investment Pte. Ltd.Sell1222202528.3710,204,351289,480,0902,597,272,387Form
5Gic, Private Ltd DirectBuy1222202529.0012,586,206364,999,974789,999,962Form